{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:32:31Z","timestamp":1782732751521,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004006","name":"Bilimsel Ara\u015ftirma Projeleri Birimi, Istanbul \u00dcniversitesi","doi-asserted-by":"publisher","award":["24114"],"award-info":[{"award-number":["24114"]}],"id":[{"id":"10.13039\/501100004006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s12032-021-01538-2","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T07:02:37Z","timestamp":1624604557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Levofloxacin might be safe to use for OSCC patients"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5836-4304","authenticated-orcid":false,"given":"Levent","family":"Aydemir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3465-1808","authenticated-orcid":false,"given":"Elif Sinem","family":"Iplik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3878-1829","authenticated-orcid":false,"given":"Baris","family":"Ertugrul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9766-4361","authenticated-orcid":false,"given":"Goksu","family":"Kasarci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5045-5095","authenticated-orcid":false,"given":"Merve Nur","family":"Atas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3885-1620","authenticated-orcid":false,"given":"Murat","family":"Ulusan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5736-8453","authenticated-orcid":false,"given":"Arzu","family":"Ergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7960-9131","authenticated-orcid":false,"given":"Bedia","family":"Cakmakoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"issue":"4","key":"1538_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1590\/1678-775720130546","volume":"22","author":"J Pan","year":"2014","unstructured":"Pan J, Zhao J, Jiang N. Oral cavity infection: an adverse effect after the treatment of oral cancer in aged individuals. J Appl Oral Sci. 2014;22(4):261\u20137. https:\/\/doi.org\/10.1590\/1678-775720130546.","journal-title":"J Appl Oral Sci"},{"issue":"5","key":"1538_CR2","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.4317\/medoral.23011","volume":"24","author":"BC Miguelanez-Medran","year":"2019","unstructured":"Miguelanez-Medran BC, et al. Oral squamous cell carcinoma of tongue: histological risk assessment. A pilot study. Med Oral Patol Oral Cir Bucal. 2019;24(5):e603\u20139. https:\/\/doi.org\/10.4317\/medoral.23011.","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"36","key":"1538_CR3","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1200\/JCO.2013.50.3870","volume":"31","author":"AK Chaturvedi","year":"2013","unstructured":"Chaturvedi AK, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31(36):4550\u20139. https:\/\/doi.org\/10.1200\/JCO.2013.50.3870.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1538_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1590\/1679-775720130317","volume":"21","author":"FR Pires","year":"2013","unstructured":"Pires FR, et al. Oral squamous cell carcinoma: clinicopathological features from 346 cases from a single oral pathology service during an 8-year period. J Appl Oral Sci. 2013;21(5):460\u20137. https:\/\/doi.org\/10.1590\/1679-775720130317.","journal-title":"J Appl Oral Sci"},{"issue":"3","key":"1538_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.14639\/0392-100X-1932","volume":"38","author":"A Paderno","year":"2018","unstructured":"Paderno A, Morello R, Piazza C. Tongue carcinoma in young adults: a review of the literature. Acta Otorhinolaryngol Ital. 2018;38(3):175\u201380. https:\/\/doi.org\/10.14639\/0392-100X-1932.","journal-title":"Acta Otorhinolaryngol Ital"},{"issue":"Suppl 2","key":"1538_CR6","doi-asserted-by":"publisher","first-page":"S491","DOI":"10.4103\/0975-7406.163511","volume":"7","author":"M Selvamani","year":"2015","unstructured":"Selvamani M, et al. Prevalence of oral squamous cell carcinoma of tongue in and around Davangere, Karnataka, India: a retrospective study over 13\u00a0years. J Pharm Bioallied Sci. 2015;7(Suppl 2):S491\u20134. https:\/\/doi.org\/10.4103\/0975-7406.163511.","journal-title":"J Pharm Bioallied Sci"},{"issue":"4","key":"1538_CR7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s12663-013-0566-8","volume":"13","author":"J Sultana","year":"2014","unstructured":"Sultana J, Bashar A, Molla MR. New management strategies of oral tongue cancer in Bangladesh. J Maxillofac Oral Surg. 2014;13(4):394\u2013400. https:\/\/doi.org\/10.1007\/s12663-013-0566-8.","journal-title":"J Maxillofac Oral Surg"},{"key":"1538_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104799","volume":"107","author":"A Almangush","year":"2020","unstructured":"Almangush A, et al. Staging and grading of oral squamous cell carcinoma: an update. Oral Oncol. 2020;107: 104799. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.104799.","journal-title":"Oral Oncol"},{"issue":"1","key":"1538_CR9","doi-asserted-by":"publisher","first-page":"7877","DOI":"10.1038\/s41598-020-64748-0","volume":"10","author":"YJ Kim","year":"2020","unstructured":"Kim YJ, Kim JH. Increasing incidence and improving survival of oral tongue squamous cell carcinoma. Sci Rep. 2020;10(1):7877. https:\/\/doi.org\/10.1038\/s41598-020-64748-0.","journal-title":"Sci Rep"},{"key":"1538_CR10","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364\u201378. https:\/\/doi.org\/10.1016\/j.ejphar.2014.07.025.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"1538_CR11","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.3892\/ijo.2015.2948","volume":"46","author":"K Yoshikawa","year":"2015","unstructured":"Yoshikawa K, et al. The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma. Int J Oncol. 2015;46(6):2364\u201370. https:\/\/doi.org\/10.3892\/ijo.2015.2948.","journal-title":"Int J Oncol"},{"issue":"23","key":"1538_CR12","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari R, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022\u201343. https:\/\/doi.org\/10.18632\/oncotarget.16723.","journal-title":"Oncotarget"},{"key":"1538_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143577","author":"Z Dong","year":"2019","unstructured":"Dong Z, et al. Biological functions and molecular mechanisms of antibiotic tigecycline in the treatment of cancers. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20143577.","journal-title":"Int J Mol Sci"},{"key":"1538_CR14","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.biopha.2018.12.119","volume":"111","author":"V Yadav","year":"2019","unstructured":"Yadav V, Talwar P. Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: an underestimated truth. Biomed Pharmacother. 2019;111:934\u201346. https:\/\/doi.org\/10.1016\/j.biopha.2018.12.119.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"1538_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/s1473-3099(03)00658-3","volume":"3","author":"A Dalhoff","year":"2003","unstructured":"Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis. 2003;3(6):359\u201371. https:\/\/doi.org\/10.1016\/s1473-3099(03)00658-3.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"1538_CR16","first-page":"455","volume":"65","author":"CM Oliphant","year":"2002","unstructured":"Oliphant CM, et al. Quinolones: a comprehensive review. Am Fam Physician. 2002;65(3):455\u201364.","journal-title":"Am Fam Physician"},{"key":"1538_CR17","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3389\/fphar.2019.00881","volume":"10","author":"E Izadi","year":"2019","unstructured":"Izadi E, et al. Levofloxacin: insights into antibiotic resistance and product quality. Front Pharmacol. 2019;10:881. https:\/\/doi.org\/10.3389\/fphar.2019.00881.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1538_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2165\/00003088-199732020-00002","volume":"32","author":"DN Fish","year":"1997","unstructured":"Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997;32(2):101\u201319. https:\/\/doi.org\/10.2165\/00003088-199732020-00002.","journal-title":"Clin Pharmacokinet"},{"key":"1538_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejmech.2012.07.004","volume":"55","author":"LR Gouvea","year":"2012","unstructured":"Gouvea LR, et al. Atypical fluoroquinolone gold(III) chelates as potential anticancer agents: relevance of DNA and protein interactions for their mechanism of action. Eur J Med Chem. 2012;55:67\u201373. https:\/\/doi.org\/10.1016\/j.ejmech.2012.07.004.","journal-title":"Eur J Med Chem"},{"issue":"15","key":"1538_CR20","doi-asserted-by":"publisher","first-page":"9039","DOI":"10.1021\/ic401220x","volume":"52","author":"J Kljun","year":"2013","unstructured":"Kljun J, et al. New uses for old drugs: attempts to convert quinolone antibacterials into potential anticancer agents containing ruthenium. Inorg Chem. 2013;52(15):9039\u201352. https:\/\/doi.org\/10.1021\/ic401220x.","journal-title":"Inorg Chem"},{"issue":"2","key":"1538_CR21","first-page":"196","volume":"5","author":"ER Mondal","year":"2004","unstructured":"Mondal ER, Das SK, Mukherjee P. Comparative evaluation of antiproliferative activity and induction of apoptosis by some fluoroquinolones with a human non-small cell lung cancer cell line in culture. Asian Pac J Cancer Prev. 2004;5(2):196\u2013204.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1538_CR22","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.biopha.2016.10.034","volume":"84","author":"M Song","year":"2016","unstructured":"Song M, et al. Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through inducing mitochondrial dysfunction and oxidative damage. Biomed Pharmacother. 2016;84:1137\u201343. https:\/\/doi.org\/10.1016\/j.biopha.2016.10.034.","journal-title":"Biomed Pharmacother"},{"key":"1538_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1159\/000239480","volume":"42","author":"T Yoshimura","year":"1996","unstructured":"Yoshimura T, et al. Immunomodulatory action of levofloxacin on cytokine production by human peripheral blood mononuclear cells. Chemotherapy. 1996;42:459\u201364. https:\/\/doi.org\/10.1159\/000239480.","journal-title":"Chemotherapy"},{"issue":"4","key":"1538_CR24","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.bbrc.2016.02.072","volume":"471","author":"M Yu","year":"2016","unstructured":"Yu M, Li R, Zhang J. Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast cancer. Biochem Biophys Res Commun. 2016;471(4):639\u201345. https:\/\/doi.org\/10.1016\/j.bbrc.2016.02.072.","journal-title":"Biochem Biophys Res Commun"},{"issue":"24","key":"1538_CR25","doi-asserted-by":"publisher","first-page":"8537","DOI":"10.1016\/j.bmc.2010.10.039","volume":"18","author":"A Korolyov","year":"2010","unstructured":"Korolyov A, et al. Novel lipophilic 7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid derivatives as potential antitumor agents: improved synthesis and in vitro evaluation. Bioorg Med Chem. 2010;18(24):8537\u201348. https:\/\/doi.org\/10.1016\/j.bmc.2010.10.039.","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"1538_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1475-2867-13-67","volume":"13","author":"J-P Sun","year":"2013","unstructured":"Sun J-P, et al. Trimethoxy-benzaldehyde levofloxacin hydrazone inducing the growth arrest and apoptosis of human hepatocarcinoma cells. Cancer Cell Int. 2013;13(1):67. https:\/\/doi.org\/10.1186\/1475-2867-13-67.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"1538_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.22088\/cjim.8.3.153","volume":"8","author":"J Masrour-Roudsari","year":"2017","unstructured":"Masrour-Roudsari J, Ebrahimpour S. Causal role of infectious agents in cancer: an overview. Casp J Intern Med Summer. 2017;8(3):153\u20138. https:\/\/doi.org\/10.22088\/cjim.8.3.153.","journal-title":"Casp J Intern Med Summer"},{"issue":"8","key":"1538_CR28","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.3390\/cancers11081174","volume":"11","author":"F Petrelli","year":"2019","unstructured":"Petrelli F, et al. Use of antibiotics and risk of cancer: a systematic review and meta-analysis of observational studies. Cancers (Basel). 2019;11(8):1174. https:\/\/doi.org\/10.3390\/cancers11081174.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1538_CR29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.emc.2018.04.001","volume":"36","author":"S Charshafian","year":"2018","unstructured":"Charshafian S, Liang SY. Rapid fire: infectious disease emergencies in patients with cancer. Emerg Med Clin N Am. 2018;36(3):493\u2013516. https:\/\/doi.org\/10.1016\/j.emc.2018.04.001.","journal-title":"Emerg Med Clin N Am"},{"issue":"5","key":"1538_CR30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.circir.2016.01.006","volume":"84","author":"VJ Villag\u00f3mez-Ort\u00edz","year":"2016","unstructured":"Villag\u00f3mez-Ort\u00edz VJ, et al. Prevalence of human papillomavirus infection in squamous cell carcinoma of the oral cavity, oropharynx and larynx. Cirug\u00eda y Cirujanos (Engl Ed). 2016;84(5):363\u20138. https:\/\/doi.org\/10.1016\/j.circir.2016.01.006.","journal-title":"Cirug\u00eda y Cirujanos (Engl Ed)"},{"issue":"5","key":"1538_CR31","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jcms.2017.01.033","volume":"45","author":"S Blatt","year":"2017","unstructured":"Blatt S, et al. Biomarkers in diagnosis and therapy of oral squamous cell carcinoma: a review of the literature. J Cranio-Maxillofac Surg. 2017;45(5):722\u201330. https:\/\/doi.org\/10.1016\/j.jcms.2017.01.033.","journal-title":"J Cranio-Maxillofac Surg"},{"issue":"1","key":"1538_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.coms.2018.08.002","volume":"31","author":"KS Ettinger","year":"2019","unstructured":"Ettinger KS, Ganry L, Fernandes RP. Oral cavity cancer. Oral Maxillofac Surg Clin N Am. 2019;31(1):13\u201329. https:\/\/doi.org\/10.1016\/j.coms.2018.08.002.","journal-title":"Oral Maxillofac Surg Clin N Am"},{"key":"1538_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10147-014-0689-z","volume":"19","author":"K Omura","year":"2014","unstructured":"Omura K. Current status of oral cancer treatment strategies: surgical treatments for oral squamous cell carcinoma. Int J Clin Oncol. 2014;19:423\u201330. https:\/\/doi.org\/10.1007\/s10147-014-0689-z.","journal-title":"Int J Clin Oncol"},{"key":"1538_CR34","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1021\/acs.chemrestox.9b00204","volume":"32","author":"L Qi","year":"2019","unstructured":"Qi L, et al. Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol. 2019;32:1469\u201386. https:\/\/doi.org\/10.1021\/acs.chemrestox.9b00204.","journal-title":"Chem Res Toxicol"},{"issue":"3","key":"1538_CR35","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1016\/j.clbc.2016.12.001","volume":"17","author":"SM Al-Bahlani","year":"2017","unstructured":"Al-Bahlani SM, et al. Cisplatin induces apoptosis via ER-mediated, calpain1 pathway in triple negative breast cancer cells. Clin Breast Cancer. 2017;17(3):e103\u201312. https:\/\/doi.org\/10.1016\/j.clbc.2016.12.001.","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"1538_CR36","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/s41419-019-2081-4","volume":"10","author":"M Kleih","year":"2019","unstructured":"Kleih M, et al. Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell Death Dis. 2019;10(11):851. https:\/\/doi.org\/10.1038\/s41419-019-2081-4.","journal-title":"Cell Death Dis"},{"issue":"5","key":"1538_CR37","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.3892\/or.2016.4680","volume":"35","author":"S Shi","year":"2016","unstructured":"Shi S, et al. ER stress and autophagy are involved in the apoptosis induced by cisplatin in human lung cancer. Oncol Rep. 2016;35(5):2606\u201314. https:\/\/doi.org\/10.3892\/or.2016.4680.","journal-title":"Oncol Rep"},{"key":"1538_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.15171\/jnp.2017.28","volume":"6","author":"Z Pezeshki","year":"2017","unstructured":"Pezeshki Z, et al. Time course of cisplatin-induced nephrotoxicity and hepatotoxicity. J Nephropathol. 2017;6:163\u20137. https:\/\/doi.org\/10.15171\/jnp.2017.28.","journal-title":"J Nephropathol"},{"issue":"12","key":"1538_CR39","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.2165\/11316640-000000000-00000","volume":"32","author":"RY Tsang","year":"2009","unstructured":"Tsang RY, Al-Fayea T, Au H-J. Cisplatin overdose toxicities and management. Drug Saf. 2009;32(12):1109\u201322. https:\/\/doi.org\/10.2165\/11316640-000000000-00000.","journal-title":"Drug Saf"},{"key":"1538_CR40","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.lfs.2020.118134","volume":"258","author":"K Bhatia","year":"2020","unstructured":"Bhatia K, Bhumika DA. Combinatorial drug therapy in cancer-New \u0130nsights. Life Sci. 2020;258:118\u201334. https:\/\/doi.org\/10.1016\/j.lfs.2020.118134.","journal-title":"Life Sci"},{"key":"1538_CR41","doi-asserted-by":"publisher","first-page":"849","DOI":"10.4236\/jct.2015.610093","volume":"6","author":"B Bhattacharya","year":"2015","unstructured":"Bhattacharya B, Mukherjee S. Cancer therapy using antibiotics. J Cancer Ther. 2015;6:849\u201358. https:\/\/doi.org\/10.4236\/jct.2015.610093.","journal-title":"J Cancer Ther"},{"issue":"4","key":"1538_CR42","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/ddr.21640","volume":"81","author":"M AlKhalil","year":"2020","unstructured":"AlKhalil M, et al. Selected pharmacotherapy agents as antiproliferative and anti-inflammatory compounds. Drug Dev Res. 2020;81(4):470\u201390. https:\/\/doi.org\/10.1002\/ddr.21640.","journal-title":"Drug Dev Res"},{"key":"1538_CR43","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/CAD.0000000000000187","volume":"26","author":"L He","year":"2015","unstructured":"He L, et al. Once-daily, oral levofloxacin monotherapy for low-risk neutropenic fever in cancer patients: a pilot study in China. Anticancer Drugs. 2015;26:359\u201362. https:\/\/doi.org\/10.1097\/CAD.0000000000000187.","journal-title":"Anticancer Drugs"},{"issue":"1","key":"1538_CR44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/jpids\/piaa015","volume":"10","author":"J Olson","year":"2021","unstructured":"Olson J, et al. Oral step-downtherapy with levofloxacin for febrile neutropenia in children with cancer. J Pediatr Infect Dis Soc. 2021;10(1):27\u201333. https:\/\/doi.org\/10.1093\/jpids\/piaa015.","journal-title":"J Pediatr Infect Dis Soc"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01538-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-021-01538-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01538-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T04:18:53Z","timestamp":1627359533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-021-01538-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1538"],"URL":"https:\/\/doi.org\/10.1007\/s12032-021-01538-2","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]},"assertion":[{"value":"11 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no conflict of interest about this article to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"87"}}